Compare Mesoblast Limited (MESO) vs abrdn Physical Palladium Shares ETF (PALL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs abrdn Physical Palladium Shares ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while abrdn Physical Palladium Shares ETF trades at $23.31. The key difference: Mesoblast Limited is trading nearer its 52-week high, abrdn Physical Palladium Shares ETF nearer its low. Which is the better fit depends on your goals.
| MESO | PALL | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Commodities - Metals/Agriculture |
52-Week High | $20.96 | $37.18 |
52-Week Low | $12.88 | $19.96 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
PALL (abrdn Physical Palladium Shares ETF) trades at $22.80, up 0.44% with a bearish technical signal from moving averages. Recent news highlights palladium's underperformance versus other precious metals, though some analysts see current price weakness as a buying opportunity. The ETF underwent a 5-for-1 forward share split on May 18, 2026, which adjusted share count without changing the underlying value.
The outlook for PALL hinges on palladium's supply-demand dynamics and industrial usage. While technical indicators suggest near-term pressure, fundamental factors like supply constraints and potential demand recovery could support prices. Key risks include Federal Reserve policy impacts and global economic conditions affecting industrial demand for palladium.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →
